Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: From the AIDS malignancy consortium and IM862 study team Academic Article uri icon


MeSH Major

  • AIDS-Related Opportunistic Infections
  • Acquired Immunodeficiency Syndrome
  • Angiogenesis Inhibitors
  • Anti-HIV Agents
  • Dipeptides
  • Sarcoma, Kaposi


  • Despite promising phase I and phase II studies, IM862 5 mg every other day was not superior to placebo and may accelerate time to progression. Highly active antiretroviral therapy alone was associated with a substantial rate of sustained tumor response and may have contributed to prior estimates of IM862 response. Therapeutic trials for AIDS-Kaposi's sarcoma must account for ongoing immune reconstitution in the setting of concurrent highly active antiretroviral therapy that may confound estimates of therapeutic activity.

publication date

  • December 2005



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.11.043

PubMed ID

  • 15598977

Additional Document Info

start page

  • 990

end page

  • 8


  • 23


  • 5